<DOC>
	<DOCNO>NCT02918292</DOCNO>
	<brief_summary>This study prospective , simultaneous , parallel phase II study one arm receiving unrelated cord blood transplantation arm receive haploidentical transplantation Severe Aplastic Anemia ( SAA ) patient . The primary objective ass overall survival ( OS ) separately 2 arm 1 year post-hematopoietic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Optimizing Cord Blood Haploidentical Aplastic Anemia Transplantation ( BMT CTN 1502 )</brief_title>
	<detailed_description>Acquired SAA rare bone marrow failure disorder estimate annual incidence 2 case per million 600 new case United States year . A major challenge treat acquire SAA management patient refractory immunosuppressant therapy ( IST ) relapse IST . HSCT curative option patient many ineligible lack suitable donor . The Blood Marrow Transplant Clinical Trials Network ( BMT CTN ) seek increase option patient use novel therapeutic strategy ( optimized preparative regimen target antithymocyte globulin ( ATG ) pharmacokinetics ( PK ) ) expand donor pool utilize UCB transplantation . The goal protocol test whether optimized approach use two alternative donor source achieve acceptable outcome SAA patient . Ideally , direct comparison two approach would allow u determine best approach . However , give 1 ) rarity disease , 2 ) fact different center often prefer different stem cell source , 3 ) fact comparison alternative donor stem cell source show similar outcome , protocol allow approach perform , plan comparison outcomes two cohort .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patient &lt; 75 year age time enrollment . 2 . Confirmed diagnosis SAA , either initial diagnosis followup assessment , define : 1 . Bone marrow cellularity &lt; 25 % marrow cellularity &lt; 50 % &lt; 30 % residual hematopoietic cell . 2 . Two three follow ( peripheral blood ) : Neutrophils &lt; 0.5 x10^9/L , Platelets &lt; 20 x10^9/L , Reticulocyte count &lt; 20 x10^9/L 3 . No suitable fully match relate ( 6/6 match human leukocyte antigen ( HLA ) A B intermediate high resolution DRB1 high resolution use DNAbased type ) unrelated donor ( 8/8 match HLAA , B , C , DRB1 high resolution use DNAbased type ) available . Search unrelated donor enrollment protocol may abandon clinical situation dictate urgent transplant best medical judgment treat provider . The definition clinical urgency may include low likelihood identify suitable match unrelated donor within 68 week referral medical need choose donor without delay beyond time . 4 . Failed least one trial immunosuppressive therapy ( IST ) refractory relapse . IST could include ATG base regimen , calcineurin inhibitor and/or high dose therapy direct treatment primary SAA . 5 . Available alternative donor : 1 . Cord blood unit ( ) must match minimum 4/6 recipient HLAA B low resolution use DNAbased type HLADRB1 high resolution use DNAbased type . Based publish report Eurocord , single unit transplantation , single unit precryopreserved total nucleated cell ( TNC ) dose must minimum 4.0 x10^7/kg recipient weight . For double cord transplant , unit must minimum 1.5 x10^7/kg precryopreserved TNC minimum total 4.0 x10^7/kg ( sum unit 1 unit 2 ) . For nonred blood cell deplete unit , minimum precryopreserved TNC dose 2.0 x10^7/kg recipient weight . 2 . HLA haplo first degree relative patient include biological parent , sibling half sibling , child 2 , 3 , 4 mismatch use DNAbased type . A unidirectional mismatch either graft versus host host versus graft direction consider mismatch . The donor recipient must identical minimum one allele ( high resolution DNAbased type ) follow genetic locus : HLAA , B , C , DRB1 . 6 . Patient and/or legal guardian must sign informed consent HSCT . 7 . In haplo cohort , donor and/or legal guardian must able sign inform consent document . 8 . In haplo cohort , potential donor must willing donate bone marrow . 9 . In haplo cohort , weight haplo donor must ≥ 20 kg . 10 . Adequate organ function define : 1 . Cardiac : Left ventricular ejection fraction ( LVEF ) rest ≥ 40 % . For patient age &lt; 13 year , shorten fraction ( SF ) ≥ 26 % echocardiogram Multi Gated Acquisition Scan ( MUGA ) may substitute LVEF . 2 . Hepatic : Total bilirubin &lt; 3.0 x upper limit normal ( ULN ) age ( patient diagnose Gilbert 's Disease allow exceed limit ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5.0 x ULN age . 3 . Renal : For patient &gt; 13.0 year age time enrollment : estimate creatinine clearance &gt; 50 mL/minute ( use CockcroftGault formula actual body weight ) . For patient &lt; 13.0 year age enrollment : Glomerular Filtration Rate ( GFR ) estimate updated Schwartz formula ≥ 90 mL/min/1.73 m2 . If estimate GFR &lt; 90 mL/min/1.73 m^2 , renal function must measure 24hour creatinine clearance nuclear GFR , must &gt; 50 mL/min/1.73 m^2 . 4 . Pulmonary : For patient &gt; 13.0 year age : Diffusing capacity lung carbon monoxide ( DLCO ) ( corrected/adjusted hemoglobin ) &gt; 40 % forced expiratory volume one second ( FEV1 ) &gt; 50 % predict ( without administration bronchodilator ) force vital capacity ( FVC ) &gt; 50 % predict . For patient &lt; 13.0 year age unable perform pulmonary function test ( PFT ) due age developmental ability : ( 1 ) evidence dyspnea rest ( 2 ) need supplemental oxygen ( 3 ) O2 saturation &gt; 92 % room air sea level ( low level allow high elevation per establish center standard care ( e.g. , Utah , 4,200 foot sea level , give supplemental oxygen unless 90 % ) ) . 11 . Karnofsky Lansky performance status ≥ 60 % . 12 . Females male childbearing potential must agree practice 2 effective method contraception time agree abstinence . 1 . Inherited bone marrow failure syndrome . At minimum , diagnosis Fanconi anemia must exclude diepoxybutane ( DEB ) equivalent test peripheral blood marrow . 2 . Clonal cytogenetic abnormality consistent premyelodysplastic syndrome ( preMDS ) MDS marrow examination ( e.g . Monosomy 7 ) . 3 . Presence antidonor HLA antibody ( positive antidonor HLA antibody define positive crossmatch test titer complementdependent cytotoxicity flow cytometric test presence antidonor HLA antibody high expression locus HLAA , B , C , DRB1 , DPB1 mean fluorescence intensity ( MFI ) &gt; 1000 solid phase immunoassay ) . 4 . Prior allogeneic stem cell transplant . 5 . Prior solid organ transplant . 6 . Known lifethreatening reaction ( i.e. , anaphylaxis ) Thymoglobulin® would prohibit use patient study require use Thymoglobulin® preparation ATG . 7 . Uncontrolled bacterial , viral , fungal infection time enrollment . Uncontrolled define currently take medication progression clinical improvement adequate medical treatment . 8 . Seropositive human immunodeficiency virus ( HIV ) . 9 . Active Hepatitis B C determine detectable viral load HBV HCV . 10 . Female patient pregnant ( per institutional practice ) breastfeeding . 11 . Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent ≤ 5 year previously allow unless approve Protocol Chairs and/or Protocol Officer . 12 . Alemtuzumab ATG within 2 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Unrelated Cord Blood ( UCB )</keyword>
	<keyword>Haploidentical Bone Marrow</keyword>
	<keyword>Hematopoietic Stem Cell Transplant ( HSCT )</keyword>
	<keyword>Severe Aplastic Anemia ( SAA )</keyword>
	<keyword>Antithymocyte Globulin ( ATG )</keyword>
</DOC>